Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of pharmaceutical composition for treating polycystic ovary syndrome

A polycystic ovary and composition technology, applied in the field of pharmaceutical composition for the treatment of polycystic ovary syndrome, can solve problems such as unfavorable quality control and large-scale production, difficulty in long-term use by patients, and heavy taste and weight of traditional Chinese medicine decoctions. Achieve good clinical application prospects, improve clinical symptoms and related biochemical indicators, and restore function

Active Publication Date: 2021-03-19
HEILONGJIANG UNIV OF CHINESE MEDICINE
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the traditional Chinese medicine decoction has a heavy taste and may cause irritation to the gastrointestinal tract, and it is inconvenient to carry, resulting in poor medication compliance of patients, making it difficult for patients to adhere to long-term use
At the same time, due to the high taste of traditional Chinese medicines, the cost and potential safety hazards are high, which is not conducive to effective quality control and large-scale production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition for treating polycystic ovary syndrome
  • A kind of pharmaceutical composition for treating polycystic ovary syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1: the preparation of oral preparation of pharmaceutical composition of the present invention

[0029] 1. An exemplary prescription is as follows:

[0030] Prescription 1: quercetin 35g, icariin 35g, aucubin 10g, alisol A 20g, 100g in total.

[0031] Prescription 2: quercetin 40g, icariin 40g, aucubin 5g, alisol A 15g, 100g in total.

[0032] Prescription 3: quercetin 30g, icariin 40g, aucubin 15g, alisol A 15g, 100g in total.

[0033] Prescription 4: quercetin 17.5g, icariin 17.5g, aucubin 5g, alisol A 10g, metformin 50g, 100g in total.

[0034] 2. Exemplary dosage forms are as follows:

[0035] Tablets: take prescription 1-3 100g, lactose 50g, compressible starch 15g, hydroxypropyl cellulose 10g, magnesium stearate 5g, 70% ethanol in an appropriate amount, and make 1000 tablets.

[0036] Capsules: take prescription 1-3 100g, starch 80g, sodium carboxymethyl starch 25g, dextrin 20g, 70% ethanol in an appropriate amount, and make 1000 capsules.

Embodiment 2

[0037] Embodiment 2: pharmacodynamic experiment

[0038] 1. Purpose of the experiment:

[0039] Investigate the effect of the pharmaceutical composition of the present invention on polycystic ovary syndrome insulin resistance rat model

[0040] 2. Experimental materials:

[0041] 2.1 Animals: SPF grade Wister female rats, weighing 250±20g, purchased from Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2018-0006.

[0042] 2.2 Instruments: 1mL syringe, gavage needle, animal cage, picric acid, capillary glass tube, high-precision zoom optical microscope, low-temperature centrifuge, blood glucose meter, microplate reader, etc.

[0043]2.3 Main medicines and reagents: quercetin, icariin, aucubin and alisol A, dehydroepiandrosterone, sesame oil for injection (US Sigma Company), Jianpi Yishen Yangxue Tongli Prescription The ointment was prepared according to the literature method (see, Hualing et al., as mentioned above), and the single medicinal material...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical composition for treating polycystic ovarian syndromes. The pharmaceutical composition is prepared from quercetin, icariin, aucubin and alisol A as raw materials according to a certain weight percentage and can be prepared into various clinically common oral preparations. The pharmaceutical composition has good therapeutic effects on a rat model withthe polycystic ovarian syndromes, at the same time can obviously reverse insulin resistance, also has no toxic or side effects, and has relatively good clinical application prospects.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to a pharmaceutical composition for treating polycystic ovary syndrome, a preparation method thereof, an oral pharmaceutical preparation and application. Background technique [0002] Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in gynecology. Its main features are menstrual disorders (such as amenorrhea, oligomenorrhea, dysfunctional uterine bleeding, etc.), hyperandrogen clinical manifestations (such as hirsutism, acne, etc.) and / or hyperandrogenemia, and polycystic ovarian changes. Anovulatory bleeding or oligomenorrhea caused by polycystic ovary syndrome, and ovulation disorder during reproductive period are important causes of infertility. PCOS patients are also accompanied by complications such as obesity, hyperinsulinemia, glucose and lipid metabolism disorders, type 2 diabetes, and cardiovascular diseases that seriously affect women's health. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61K31/56A61K31/352A61K31/155A61P15/08A61P3/10A61P5/50
CPCA61K31/155A61K31/352A61K31/56A61K31/7048A61P3/10A61P5/50A61P15/08A61K2300/00
Inventor 郝松莉陈强徐芳
Owner HEILONGJIANG UNIV OF CHINESE MEDICINE